Cantargia utvecklar antikroppen CAN04 för cancerbehandling. CAN04 undersöks i den kliniska fas I/IIa-studien CANFOUR. CAN04 är riktad

I den del av CANFOUR som innefattar PDAC behandlas fortfarande 9 av 31 patienter i den primära kohorten med CAN04 i kombination med gemcitabin och nab-paclitaxel. En interimsanalys av 20 patienter i oktober 2020 visade på s.k. respons i 40% av patienterna (inkluderande 2 patienter som inte behandlats tillräckligt länge för en andra, bekräftande CT-scan), vilket är högre än historiska

1 jun 2019 tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody CANFOUR – Phase I study design. 5. Prof. Ahmad Awada. 6. mar 2020 CANFOUR - En doseopptrappingsstudie for å evaluere sikkerheten og toleransen av flere doser med CAN04-antistoff hos pasienter med solide See Tweets about #canfour on Twitter. #Cantargia Reports Interim #Data from Phase 2A #CANFOUR Trial of CAN04 in #Pancreatic and #LungCancers Cantargia reports treatment of first patient with antibody CAN04 in the phase IIa part of CANFOUR trial.

Canfour can04

Huvudprojektet, antikroppen CAN04, studeras i den kliniska fas I/IIa-studien CANFOUR med primärt fokus mot icke-småcellig lungcancer och bukspottskörtelcancer. Studien genomförs som både monoterapi och kombinationsterapi. According to the study protocol, the patients continue CAN04 (nidanilimab) treatment for biomarker and efficacy evaluation. Based on the positive outcome of the phase I safety evaluation, the phase IIa part of the trial can be started as planned.

20 Aug 2020 The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung 16 Jun 2017 Cantargia's lead preclinical-stage anticancer candidate CAN04 is another The prospective trial has been designated CANFOUR.

08.10.2020 - STOCKHOLM, Oct. 8, 2020 /PRNewswire/ - Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 …

Thereby, CAN04 can counteract the contribution of the IL-1 The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. CAN04 increased the anti-tumor effects in mice when combined with different registered platinum-based therapies (cisplatin, carboplatin or oxaliplatin) in either a patient-derived NSCLC model or CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is focused on CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining first line chemotherapy combination with two different standard regimes in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC), as well as monotherapy in late stage patients (www.clinicaltrials.gov).

Detailed Description: CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP). The CAN04 strategy is to attack the IL1RAP target molecule using an effective antibody-based cancer treatment.

CAN04 increased the anti-tumor effects in mice when combined with different registered platinum-based therapies (cisplatin, carboplatin or oxaliplatin) in either a patient-derived NSCLC model or CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is focused on CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining first line chemotherapy combination with two different standard regimes in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC), as well as monotherapy in late stage patients (www.clinicaltrials.gov). The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1a and IL-1ß signaling.

In the interim 2019-01-28 CAN04-antikroppen är riktad mot IL1RAP som finns i ett stort antal cancerformer. De första sjukhusen i den kliniska fas I/IIa prövningen CANFOUR initierades nyligen och rekrytering av patienter pågår. I enlighet med protokollet behandlas patienterna i grupper om tre. The results from the CANFOUR study for Cantargia's candidate CAN04 are imminent, due in Q4 2019 and early 2020. The outcome will, in our view, represent a major valuation trigger for the share and potentially also lead to a partnership deal.
Stockholmsnatt quincy

Verkningsmekanism tros vara en minskning av inflammation i tumörens´mikromiljön + ADCC + stimulering av NK celler. Studie population är Bukspottskörtelcancer och Icke småcellig lungcancer.

Publicerad: 2020-10-02 (Cision) Cantargia AB: Cantargia rapporterar att första patienten behandlats med CAN04 i en fas I studie i USA som studerar kombination med pembrolizumab CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung Vi tror att ändå att besked breddat kliniskt program för CAN04, nya CANFOUR-data och ett ökade fokus på CAN10 skapar förutsättningar för fortsatt positiv utveckling för aktien.
Matematik 2b bok

trygghandel.se bra
christel larsson göteborgs universitet
james ascher
greenpeace protest
lundsby biogas proff
det går inte att hitta något unikt index för referensfältet i primärtabellen

Prekliniska data visar att CAN04 kan öka effekten av cellgifter. CAN04 studeras i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker

Likviden möjliggör en utökad satsning på bolagets huvudprojekt CAN04 (nidanilimab) med en ny klinisk studie i USA och en expansion av den mest lovande subgruppen patienter i den pågående kliniska studien CANFOUR.